SequelSEC

RAPID MICRO BIOSYSTEMS, INC. RPID

Laboratory Analytical Instruments · CIK 0001380106 · Fiscal year ends 1231

Revenue
$33.59M
Fiscal year ended 2025-12-31
Operating income
-$47.39M
Fiscal year ended 2025-12-31
Free cash flow
-$31.91M
Fiscal year ended 2025-12-31

Valuation, from the filing

Public float$103.56MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float / revenue3.1×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity3.1×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Laboratory Analytical Instruments filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth19.7%95th
FCF margin-95.0%17th
Net margin-140.3%23th
Operating margin-141.1%25th
R&D / revenue40.5%74th
Long-term debt / equity0.57x62th
SBC / revenue12.0%55th
CapEx / revenue2.5%47th
Current ratio3.31x48th

RAPID MICRO BIOSYSTEMS, INC. (RPID) reported revenue of $33.59M and net income of -$47.12M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from RAPID MICRO BIOSYSTEMS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Laboratory Analytical Instruments.

Income

RAPID MICRO BIOSYSTEMS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$33.59M$28.05M$22.52M$17.13M$23.23M$16.08M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$47.39M-$49.92M-$56.56M-$63.22M-$47.23M-$30.54M
Net income-$47.12M-$46.89M-$52.47M-$60.81M-$73.52M-$37.08M
Research & development$13.60M$14.60M$12.82M$12.87M$9.78M$6.53M
Weighted-average diluted sharesshares 44.68Mshares 43.58Mshares 43.02Mshares 42.45Mshares 19.78MUnavailable
Pretax income-$47.08M-$46.87M-$52.44M-$61.38M-$73.43M-$36.94M
Income tax expense$40.00K$22.00K$31.00K-$576.00K$91.00K$134.00K
Diluted EPS$-1.05$-1.08$-1.22$-1.43$-3.94$-126.11
Selling, general & administrative$34.84M$35.21M$38.26M$41.81M$29.71M$15.94M
General & administrative$22.75M$21.95M$24.94M$26.82M$17.90M$9.98M
Selling & marketing$12.08M$13.27M$13.32M$14.99M$11.82M$5.96M

Balance

RAPID MICRO BIOSYSTEMS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$20.03M$16.91M$24.28M$27.06M$178.39M$30.08M
Total assets$74.85M$98.17M$143.45M$190.65M$241.17M$70.00M
Current assets$61.17M$80.92M$120.42M$138.58M$218.12M$62.15M
Total liabilities$41.65M$22.82M$25.46M$26.48M$20.19M$45.18M
Current liabilities$18.49M$17.56M$18.99M$19.05M$18.17M$15.54M
Total equity incl. NCI$33.21M$75.35M$117.99M$164.17M$220.98M-$127.01M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$151.83M
Inventory$17.59M$20.20M$19.96M$21.19M$15.67M$8.96M
Accounts receivable$3.13M$7.52M$5.53M$5.37M$5.00M$4.99M
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$18.90M$0Unavailable$0$0$24.81M
Accounts payable$4.14M$2.54M$1.97M$5.43M$3.94M$4.47M

Cash flow

RAPID MICRO BIOSYSTEMS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$31.06M-$44.15M-$45.08M-$58.55M-$54.96M-$31.00M
Capital expenditures$850.00K$1.36M$1.84M$6.74M$3.22M$690.00K
Investing cash flow$14.33M$36.66M$42.15M-$93.47M-$13.29M-$15.67M
Financing cash flow$19.77M$203.00K$149.00K$693.00K$216.74M$64.23M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$4.03M$3.87M$4.75M$4.02M$1.84M$533.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$3.25M$3.36M$3.10M$2.84M$1.53M$1.51M

Derived

RAPID MICRO BIOSYSTEMS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$31.91M-$45.52M-$46.93M-$65.29M-$58.18M-$31.69M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-141.1%-178.0%-251.2%-369.0%-203.3%-190.0%
FCF margin-95.0%-162.3%-208.4%-381.1%-250.4%-197.1%
SBC / revenue12.0%13.8%21.1%23.5%7.9%3.3%
Current ratio3.31x4.61x6.34x7.27x12.01x4.00x
Revenue YoY growth19.7%24.6%31.4%-26.3%44.5%Unavailable
Net margin-140.3%-167.2%-233.0%-354.9%-316.5%-230.6%
R&D / revenue40.5%52.0%56.9%75.1%42.1%40.6%
CapEx / revenue2.5%4.9%8.2%39.3%13.8%4.3%
Long-term debt / equity0.57xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RPID in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-07View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-09View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.